Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

Breakthrough of The Year, Science has named the development of lenacapavir – a promising new injectable drug that prevents HIV infection. The award also recognizes related work surrounding gaining a ...

The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...

Deaths from HIV/AIDS are ten times lower than at the peak of the epidemic, and new research could drive that down even more.

Gilead is going to start testing a drug it believes could prevent HIV infection with just a single shot every year.

Musk has argued in favor of regulating AI. But venture capitalists like Andreessen, who founded Andreessen Horowitz, a VC ...

Want to stay on top of the science and politics driving biotech today ... The drug is another formulation of lenacapavir, a ...

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...

LOS ANGELES, Dec. 13 (Xinhua) -- An injectable HIV drug with novel mechanism was named on Thursday by the influential U.S. journal "Science" as Breakthrough of the Year. The drug, named lenacapavir, ...